Acadia Pharmaceuticals Inc [NASDAQ: ACAD] plunged by -$0.35 during the normal trading session on while it closed the day at $18.00.
Acadia Pharmaceuticals Inc stock has also gained 1.98% of its value over the past 7 days. However, ACAD stock has inclined by 4.71% in the 3 months of the year. Over the past six months meanwhile, it has lost -35.67% and lost -42.51% year-on date.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for ACAD stock reached $2.97 billion, with 164.65 million shares outstanding and 164.01 million shares in the current float. Compared to the average trading volume of 1.72M shares, ACAD reached a trading volume of 2633227 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Acadia Pharmaceuticals Inc [ACAD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ACAD shares is $27.32 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ACAD stock is a recommendation set at 1.62. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BMO Capital Markets have made an estimate for Acadia Pharmaceuticals Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on June 27, 2024. While these analysts kept the previous recommendation, Needham dropped their target price from $36 to $32. The new note on the price target was released on March 12, 2024, representing the official price target for Acadia Pharmaceuticals Inc stock. Previously, the target price had yet another drop from $39 to $25, while Mizuho kept a Neutral rating on ACAD stock.
The Average True Range (ATR) for Acadia Pharmaceuticals Inc is set at 0.62, with the Price to Sales ratio for ACAD stock in the period of the last 12 months amounting to 3.65. The Price to Book ratio for the last quarter was 6.40, with the Price to Cash per share for the same quarter was set at 2.85. Price to Free Cash Flow for ACAD in the course of the last twelve months was 46.72 with Quick ratio for the last quarter at 1.86.
ACAD stock trade performance evaluation
Acadia Pharmaceuticals Inc [ACAD] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.98. With this latest performance, ACAD shares gained by 21.29% in over the last four-week period, additionally sinking by -35.67% over the last 6 months – not to mention a drop of -45.44% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ACAD stock in for the last two-week period is set at 66.08, with the RSI for the last a single of trading hit 67.40, and the three-weeks RSI is set at 62.45 for Acadia Pharmaceuticals Inc [ACAD]. The present Moving Average for the last 50 days of trading for this stock 15.80, while it was recorded at 18.15 for the last single week of trading, and 21.28 for the last 200 days.
Acadia Pharmaceuticals Inc [ACAD]: An insightful look at the core fundamentals
Acadia Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.86 and a Current Ratio set at 2.04.
Acadia Pharmaceuticals Inc [ACAD]: Institutional Ownership
The top three institutional holders of ACAD stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.5034%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $178.43 billion in ACAD stocks shares; and BERKSHIRE HATHAWAY INC, currently with $135.36 billion in ACAD stock with ownership which is approximately 5.1238%.
